Claudia Ollauri-Ibáñez

5PUBLICATIONS
29CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 27, 2026
The Src inhibitor peptide TAT-Cx43266-283 improves survival in an intracranial murine model of lung cancer brain metastasis.

Pilar Cerveró-García, Enrique Jiménez-Madrona, Andrea Álvarez-Vázquez

|Mar 20, 2024
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.

Andrea Álvarez-Vázquez, Laura San-Segundo, Pilar Cerveró-García

|Sep 10, 2021
Impairment of Autophagic Flux Participates in the Antitumor Effects of TAT-Cx43266-283 in Glioblastoma Stem Cells.

Sara G Pelaz, Claudia Ollauri-Ibáñez, Concepción Lillo

|Apr 03, 2021
Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?

Claudia Ollauri-Ibáñez, Blanca Ayuso-Íñigo, Miguel Pericacho

|Jan 15, 2021
Use of Antiangiogenic Therapies in Pediatric Solid Tumors.

Claudia Ollauri-Ibáñez, Itziar Astigarraga

Pageof 1